These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Mortality and metformin use in patients with advanced chronic kidney disease. Lalau JD; Kajbaf F; Arnouts P; de Broe M Lancet Diabetes Endocrinol; 2015 Sep; 3(9):680-1. PubMed ID: 26298570 [No Abstract] [Full Text] [Related]
9. Therapy: Risk of metformin use in patients with T2DM and advanced CKD. Schernthaner G; Schernthaner-Reiter MH Nat Rev Endocrinol; 2015 Dec; 11(12):697-9. PubMed ID: 26284445 [TBL] [Abstract][Full Text] [Related]
10. Mortality and metformin use in patients with advanced chronic kidney disease--Authors' reply. Hung SC; Chang YK; Liu JS; Hsu CC; Tarng DC Lancet Diabetes Endocrinol; 2015 Sep; 3(9):681. PubMed ID: 26298571 [No Abstract] [Full Text] [Related]
11. Don't throw the baby out with the bath water: mortality with combination metformin and sulfonylurea. Tayek JA Diabetes Metab Res Rev; 2007 Feb; 23(2):85-6. PubMed ID: 17262894 [No Abstract] [Full Text] [Related]
12. Chronic kidney disease: Metformin increases risk of mortality in patients with advanced chronic kidney disease. Edwards JK Nat Rev Nephrol; 2015 Aug; 11(8):443. PubMed ID: 26149836 [No Abstract] [Full Text] [Related]
14. Selling safety--lessons from muraglitazar. Brophy JM JAMA; 2005 Nov; 294(20):2633-5. PubMed ID: 16239638 [No Abstract] [Full Text] [Related]
15. Metformin in chronic kidney disease: more harm than help? Kalantar-Zadeh K; Rhee CM Lancet Diabetes Endocrinol; 2015 Aug; 3(8):579-81. PubMed ID: 26094106 [No Abstract] [Full Text] [Related]
16. Rosiglitazone and cardiovascular risk. Psaty BM; Furberg CD N Engl J Med; 2007 Jun; 356(24):2522-4. PubMed ID: 17517854 [No Abstract] [Full Text] [Related]
17. Safety of metformin in Type 2 diabetes mellitus. Baigent C; Peto R Diabet Med; 1999 Feb; 16(2):89-90. PubMed ID: 10229300 [No Abstract] [Full Text] [Related]
18. Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW Diabetes Res Clin Pract; 2017 Jan; 123():199-208. PubMed ID: 28056431 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register. Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621 [TBL] [Abstract][Full Text] [Related]
20. The UK Prospective Diabetes Study. Evans M Lancet; 1998 Dec; 352(9144):1932-3; author reply 1934. PubMed ID: 9863807 [No Abstract] [Full Text] [Related] [Next] [New Search]